CIK 0001984086 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Septerna, Inc.
Sign in to watch- Ticker
- SEPN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843891440
- Phone
- 650-338-3533
- Business address
- 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,210,085
- in 3 filings, $4.2M under 10b5-1 plans
Net −$4,210,085. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-26 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-26 | Bassan Abraham Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-26 | Sharp Shalini Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-26 | Coulie Bernard Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-26 | Tong Jeffrey K Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-26 | Gottesdiener Keith Michael Director | Grant or award · Stock Option (Right to Buy) | +11,260 | 11,260 | ||
| 2026-06-26 | Simson Jake Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-26 | Ezekowitz Alan Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +10,529 | $2.76 | $29K | 106,941 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise 10b5-1 | +4,471 | $11.70 | $52K | 111,412 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −8,000 | $35.10 | $281K | 103,412 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Sale 10b5-1 | −7,000 | $35.97 | $252K | 96,412 |
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,529 | 10,376 | ||
| 2026-06-22 | Long Daniel D. SVP, Drug Discovery | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,471 | 25,529 | ||
| 2026-06-12 | Shaikhly Samira Chief People Officer | Option exercise 10b5-1 | +6,250 | $11.70 | $73K | 7,043 |
| 2026-06-12 | Shaikhly Samira Chief People Officer | Sale 10b5-1 | −6,250 | $35.08 | $219K | 793 |
| 2026-06-12 | Shaikhly Samira Chief People Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,250 | 23,750 | ||
| 2026-06-01 | Shaikhly Samira Chief People Officer | Option exercise 10b5-1 | +4,355 | $1.55 | $7K | 5,148 |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Option exercise 10b5-1 | +943 | $2.76 | $3K | 6,091 |
| 2026-06-01 | Shaikhly Samira Chief People Officer | Option exercise 10b5-1 | +637 | $2.76 | $2K | 6,728 |
Page 3 of 8 · 148 trades